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We characterized highly selective receptors for PACAP, the pituitary adenylate cyclase activating peptide, in the tumoral acinar cell line AR 4-25 
derived from the rat pancreas. PACAP, a novel hypothalamic peptide related to vasoactive intestinal peptide (VIP), was tested as the full natural 
3%residue peptide (PACAP-38) and as an N-terminal amidated 27-residue derivative (PACAP-27). The binding sites showed considerable affinity 
for Pz51]PACAP-27 (&=0.4 nM) and PACAP-38, while their afhity for VIP and the parent peptide helodermin was lOOO-fold lower. These recep- 
tors were coupled to adenylate cyclase, the potency of PACAP- and PACAP- (&, = 0.2 nM) being much higher than that of VIP (& = 100 
nM) and helodermin (K,, = 30 nM). Chemical cross-linking of rz51]PACAP-27 followed by SDS-PAGE and autoradiography revealed aspecifically 
cross-linked peptide with an IU, of 68000 (including 3000 for one PACAP- molecule). 
Pituitary adenylate cyclase activating peptide receptor; Vasoactive intestinal peptide; Helodermin; Adenylate cyclase; Pancreatic acinar cell line 
AR 4-25; (Rat) 
1. INTRODUCTION 
The AR 4-25 cell line derives from azaserine-induced 
hyperplastic nodules of the rat exocrine pancreas [ 11. 
CCKA [2], CCKn [3], bombesin [4], somatostatin [5], 
insulin [6], substance P [7], EGF [8], FGF [9], and VIP 
[lo] receptors have already been characterized on the 
cell surface. In contrast, secretin receptors were 
detected neither in binding studies nor by adenylate 
cyclase activation, contrasting with the presence of such 
receptors in non-transformed rat pancreatic acinar 
cells. In the present study, we tested the possible in- 
teraction of PACAP- and a shorter derivative 
(PACAP-27) on AR 4-25 cell membranes. PACAP- 
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is a newly discovered peptide of ovine hypothalamic 
origin [l l] that presents 68% homology with VIP in its 
N-terminal (l-28) moiety. Our assumption was that 
PACAP would interact with the VIP receptors of AR 
4-25 cells. We found, to our surprise, that PACAP in- 
teracted with considerable affinity with highly specific 
PACAP receptors, coupled to adenylate cyclase, and 
distinct from VIP-preferring receptors. The functional 
and structural characteristics of this new type of recep- 
tor are described in the present paper. 
2. MATERIALS AND METHODS 
2.1. Peptide synthesis 
The full 38 residue peptide (PACAP-38) and its N-terminal 
amidated 27 residue derivative (PACAP-27-NHz, quoted below as 
PACAP-27) were synthesized by solid phase techniques as previously 
described [11,121. All other peptides and chemicals were of the highest 
analytical grade available. 
2.2. Peptide radioiodination 
PACAP- was radioiadinated by the chloramine T method and 
purified as described in [13]. Tracer specific radioactivity was 1 
mCi/O. 1 nmol. 
2.3. Binding studies 
Binding studies with [“‘I]PACAP-27 were conducted as described 
for VIP receptor identification [14]. Briefly, membranes were in- 
cubated at 37°C in a total vol. of 0.12 ml containing 50 mM 
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Trislmaleate, 5 mM MgC12, 1 .O% (w/v) bovine serum albumin, 100 
KIU/ml Trasylol, 0.5 mg/ml bacitracin (PH 7.4) and [‘251]PACAP-27 
(10000 to 16OOW cpm/assay in saturation experiments, and 20000 
cpmfassay in standard assay con~tions, corresponding to a final 
tracer concentration of 0.2 nM). Non-specific binding was determined 
in the presence of 0.1 FM PACAP- in competitive studies and 0.3 
PM PACAP- for Scatchard plots. The separation of membrane 
bound and free radioactivities was achieved by rapid filtration 
through glass-fiber filters (GF/C; Whatman, Maidstone, Kent, 
England) and presoaked for 24 h in 0.1% pofy(ethyleneimine). 
2.4. Adenylate cyclase assay 
An adenylate cyclase assay was performed as previously described, 
at 37”C, in the presence of 0.1 PM GTP, and in a final volume of 0.06 
ml [lJ]. 
2.5. Ceil cuitwe and crude membrane preparation 
The pancreatic acinar cell line AR 4-2J was m~n~ned as a sub- 
confluent culture in Dulbecco’s modified Eagle’s medium enriched 
with penicillin, streptomycin, amphotericin B, and 10% (v/v) fetal 
calf serum. Cells were grown in 175 cm’ flasks at 37°C in an at- 
mosphere of 5% CO2 in air at 100% humidity. For membrane 
preparation, cells were mechanically detached, washed with fresh 
culture medium without added fetal calf serum, pelleted at 50 x g for 
10 min, lysed with 1 mM NaHC03 and quickly frozen in liquid Nz. 
The lysate was then defrosted, centrifuged at 4°C for 10 min at 
2000 x g and the supernatant was centrifuged for 10 min at 
15000 x g. The pellet was resuspended in 1 mM NaHCOr and im- 
mediately tested. 
2.6. Cross-linking of [‘251]PACAP-27 to AR 4-2J membranes 
Membranes were incubated for 20 min at 37°C with 0.5 nM 
[“‘I]PACAP-27 in the medium used for the binding assay (see 
above). After incubation, membranes were washed twice by cen- 
trifugation/resuspension i cold 50 mM phosphate buffer (pH 7.4) 
containing 150 mM NaCl and resuspended in the same buffer. Disuc- 
cinimidyl suberate (1 mM final concentration) was dissolved im- 
mediately before use in dry dimethylsulfoxide and added to 99 vol. of 
the membrane suspension. After a 30-min incubation at 4*C, mem- 
branes were washed twice in cold phosphate buffer (see above) then 
solubilized in an electrophoresis ample buffer made of 125 mM 
Tris/HCl (pH 6.8) enriched with 5% (w/v) SDS, 1% (w/v) 
dithiothreitol, 4% (w/v) 2-mercaptoethanol, 10% (w/v) sucrose and 
0.02% (w/v) Bromophenol blue. SDS-PAGE was performed under 
reducing conditions as in [16] with a 12% homogeneous polyacryl- 
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Fig.1. (A) Kinetics of specific [*251]PACAP-27 binding to AR 4-23 
membranes. The results are representative of experiments performed 
in duplicate on 3 different preparations. (B) Kinetics of dissociation 
of prebound (*2SI]PACAP-27. After a 20-min incubation of mem- 
branes in the presence of [‘*‘I]PACAP-27, 0.1 PM unlabelled 
PACAP- was added in the absence (0) or presence (e) of 10 PM 
GTP, to induce dissociation. The results are the means of experiments 
performed in duplicate on 3 different preparations. (C) Scatchard 
representation of a saturation curve of [“sI]PACAP-27 binding to 
AR 4-23 membranes. The results are representative of 3 experiments. 
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Fig.2. Inhibition of [“‘I]PACAP-27 binding to AR 4-25 membranes 
by increasing concentrations of unlabelled PACAP- (0), 
PACAP- (A), VIP (o), helodermin (D), and VIP (10-28) (A). The 
results are expressed in % of tracer specifically bound in the absence 
of unlabelled peptide and are the means of experiments performed in 
duplicate on at least 3 different preparations. 
amide separating gel (180 x 200 x 1.5 mm). Autoradiographies 
were conducted for two weeks at - 80°C. 
2.7. Protein concentration 
The protein concentration was determined by the method of Lowry 
et al. [17] using bovine serum albumin as a standard. 
3. RESULTS 
Specific [r2’I]PACAP-27 binding to AR 4-25 mem- 
branes was rapid (fig.lA), reversible (fig.lB) and 
saturable (fig.lC). At 37°C apparent binding 
equilibrium was attained after 15 min. Tracer bound 
after 20 min dissociated with a fl_2 of 20 min, as studied 
by isotopic dilution. This 81-2 was transiently reduced to 
4 min in the added presence of 10 FM GTP. The Scat- 
chard plot of the saturation curve of tracer binding 
revealed one class of binding sites with a Kd of 0.4 nM. 
PACAP- and PACAP- were equally potent 
(I& of 1.0 nM) to inhibit the binding of 0.2 nM 
[*“I]PACAP-27 while VIP and helodermin were both 
lOOO-fold less potent. Ten PM VIP (10-28) inhibited 
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Fig.3. Adenylate cyclase stimulation of AR 4-25 membranes by in- 
creasing concentrations of PACAP- (0), PACAP- (A), VIP 
(o), and helodermin (D) in the presence of 10,~M GTP. The results, 
expressed in pmol cyclic AMP produced. min-’ . mg protein-’ are the 
means of experiments performed in duplicate on 3 different prepara- 
tions. 
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tracer binding by 30% (fig.2). PHI, PHI-Gly and PHV 
from rat [18], and porcine secretin, porcine glucagon 
and human GRF (l-29)-NH2 were unable, at a 1 PM 
concentration, to significantly affect tracer binding (not 
shown). 
PACAP- and PACAP- were equally potent and 
efficient in stimulating adenylate cyclase with a Ka,* of 
0.2 nM (fig.3). VIP and helodermin showed lower 
potency (&t of 100 and 30 nM, respectively) and 
reduced efficacy (30% and SO%, respectively, of the 
maximum effects of PACAP- and PACAP-38). We 
were unable to consistently inhibit the stimulatory ef- 
fects of PACAP- and PACAP- with high concen- 
trations of VIP or helodermin (data not shown). 
After [‘2”I]PACAP-27 cross-linking to AR 4-25 
membranes, SDS-PAGE followed by autoradiography 
revealed a unique M, 68 000 band, under reducing con- 
ditions (fig.4). The labelling of this band was markedly 
reduced when membranes were incubated in the 
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Fig.4. Cross-linking of [‘*sI]PACAP-27 to AR 4-2J membranes. 
Membranes were incubated with [12SI]PACAP-27 in the absence or 
presence of 0.1 PM unlabelled PACAP- or unlabelled VIP. Cross- 
linking was performed by disuccinimidyl suberate and, after washing, 
membranes were solubiliz~ and submitted to SDS-PAGE under 
reducing conditions. Autoradiographies were conducted for two 
weeks at - 80°C (see section 2). Similar rest&s were obtained when 
the incubation buffer contained ovalbumin instead of bovine serum 
presence of 0.1 r/M PACAP-27, but was unaffected by 
the presence of 0.1 pM VIP in the incubation medium. 
4. DISCUSSION 
The present data demonstrate unambiguously the 
presence, on membr~es from the rat pancreatic acinar 
cell line AR 4-2J, of new specific binding sites for the 
novel hypothalamic peptide PACAP. These binding 
sites, when tested with the radioligand 
[tz51]PACAP-27, showed high selectivity as they 
recognized only PACAP- and PACAP- with high 
affinity (1C50 of 1 nM). Parent peptides such as VIP, 
PHI, secretin, helodermin, GRF and glucagon (se- 
quences illustrated in table 1) were at least IOOO-fold less 
potent than PACAP. This high degree of selectivity was 
comparable to that observed for secretin receptors and 
VIP receptors when tested for, respectively, VIP and 
secretin interactions 1191. PACAP binding sites had an 
iM, of 68000 (including 3000 for one PACAP- 
molecule), a value somewhat higher than that of 61000 
for VIP binding sites in the same cell line, under reduc- 
ing conditions [lo]. 
The present PACAP binding sites were coupled to 
adenylate cyclase and the Kact for both PACAP- and 
PACAP- was lower (0.2 nM) than their & in binding 
studies, suggesting that only a fraction of receptors 
needed to be occupied for maximal enzyme activation. 
Our data on VIP- and helodermin-mediated adenylate 
cyclase activation did not establish whether these pep- 
tides interacted with PACAP receptors or with specific 
low-affinity VIP/helodermin receptors. We favor the 
second hypothesis for two reasons: (i) the discrepancy 
between the VIP and helodermin concentrations re- 
quired for PACAP receptor occupancy and adenylate 
cyclase activation was not due to receptor spareness, as 
the first two peptides showed lower intrinsic activity 
than PACAP; (ii) high- and low-affinity VIP receptors 
that also recognize helodermin, have both been iden- 
tified in AR 4-25 cells [lo]. 
PACAP- was isolated from ovine hypothalamus 
on the basis of its ability to stimulate rat pituit~ 
adenylate cyclase [I I] but little is known on other 
biological effects. The existence of PACAP- was 
deduced, on theoretical ground only, when considering 
that the consensus equence Gly-Lys-Arg in PACAP- 
could conceivably facilitate the generation of an 
amidated peptide. A much higher accumulation of 
cyclic AMP is observed in pituitary cells submitted to 
PACAP in place of any other peptide [I I]. The in vivo 
vasodepressor activity of PACAP suggests that it could 
interact with peripheral VIP receptors but extrahypo- 
thalamic locations of PACAP have not yet been 
established. Our discovery of specific PACAP recep- 
tors in an acinar cell line derived from the exocrine pan- 
creas suggests, however, that PACAP could be a new 
brain-gut peptide. 
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